Ensysce Biosciences (ENSC) Income from Continuing Operations (2018 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Income from Continuing Operations of 3747464.0 for Q3 2025, down 684.92% year-over-year from 640683.0 in Q3 2024, and down 113.69% quarter-over-quarter from 1753675.0 in Q2 2025.
Ensysce Biosciences (ENSC) Income from Continuing Operations (2018 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Income from Continuing Operations for 8 consecutive years, with 3747464.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Income from Continuing Operations fell 684.92% year-over-year to 3747464.0; the TTM figure through Sep 2025 stood at 11051676.0 (down 45.52% YoY), while the FY2024 annual figure was 8011731.0, up 35.48% from the prior year.
- Income from Continuing Operations retreated to 3747464.0 in Q3 2025 per ENSC's latest filing, from 1753675.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 640683.0 in Q3 2024 and bottomed at 54127348.0 in Q2 2021.
- Historically, Income from Continuing Operations has averaged 6757021.37 across 5 years, with a median of 3091029.0 in 2024.
- Annual changes were most pronounced in 2021 — Income from Continuing Operations slumped 86318.48% — and 2024, when it soared 123.6%.
- Ensysce Biosciences' Income from Continuing Operations stood at 2104226.0 in 2021, then slumped by 199.56% to 6303447.0 in 2022, then jumped by 49.85% to 3161255.0 in 2023, then fell by 13.22% to 3579169.0 in 2024, then slipped by 4.7% to 3747464.0 in 2025.
- Business Quant data shows ENSC's Income from Continuing Operations at 3747464.0 in Q3 2025, 1753675.0 in Q2 2025, and 1971368.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Ensysce Biosciences | 942,649.19 | -3.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -3.75 Mn |
| Jun 30, 2025 | -1.75 Mn |
| Mar 31, 2025 | -1.97 Mn |
| Dec 31, 2024 | -3.58 Mn |
| Sep 30, 2024 | 640,683.00 |
| Jun 30, 2024 | -1.98 Mn |
| Mar 31, 2024 | -3.09 Mn |
| Dec 31, 2023 | -3.16 Mn |
| Sep 30, 2023 | -2.71 Mn |
| Jun 30, 2023 | -2.29 Mn |
| Mar 31, 2023 | -2.56 Mn |
| Dec 31, 2022 | -6.30 Mn |
| Sep 30, 2022 | -6.17 Mn |
| Jun 30, 2022 | -7.10 Mn |
| Mar 31, 2022 | -4.82 Mn |
| Dec 31, 2021 | -2.10 Mn |
| Sep 30, 2021 | -19.83 Mn |
| Jun 30, 2021 | -54.13 Mn |
| Mar 31, 2021 | -1.71 Mn |
| Dec 31, 2020 | -1.34 Mn |